Gene & Cell Therapy and Rare Diseases’ Research
We conduct extensive research into the rapidly evolving gene and cell therapy and rare diseases arena to empower clients to win. Our strategic insights identify key players and developments, tailored to support BioPharma partners across R&D, clinical, regulatory, and commercial endeavors.
The gene and cell therapy space has advanced rapidly, with new assets targeting therapeutic areas such as oncology, immunology, cardiovascular, CNS, and rare diseases. With multiple companies active and new approvals happening, it’s critical to get strategic insights, whether you are a BioPharma company or investor.
Our services include (amongst others):
For BioPharma clients:
- Market and competitor insights on R&D, clinical development and commercial activities
- Extensive congress coverage, supporting brand owners with up-to-date intelligence
- Landscape analysis strengthened by expert interviews
- BD&L support
For Investors:
- Due diligence research
- New opportunity identification
- Access to experts’ opinion through a combination of in-house expertise and conduct of bespoke interviews
We also invite you to join our LinkedIn Gene, Cell and RNA Therapy Strategy Network group – a hub for networking and information.
Want to better understand and succeed in this complex space? Let’s connect!
Reach out to info@lqventures.com to learn more about our strategic consulting and research capabilities.
September 9, 2026
Women’s Health Strategic Roundup | Aug 04 – Sep 08, 2026
September 4, 2026
Respiratory Strategic Roundup | Jul 31–Sep 03, 2026
September 3, 2026
Cell and Gene Therapy Strategic Roundup | Jul 29 – Aug 31, 2026
September 2, 2026
Mobile Health App Trends in H1 2026: Growth Outpaces Clinical Maturity
September 1, 2026
Healthcare and Pharma Trends H1 2026: Innovation Shifts Toward Real-World Delivery
September 1, 2026
Obesity Strategic Roundup | Jul 28 – Aug 31 , 2026
August 27, 2026
Cardiovascular Strategic Roundup | July 23–August 26, 2026
August 26, 2026
Lundbeck Expands EVERSANA AI Commercialization | Lucid Diligence Brief
August 26, 2026
Neuroscience Strategic Roundup | July 21–August 25, 2026
August 25, 2026
Endocrinology Strategic Roundup | July 21–August 24, 2026
August 21, 2026
Public Health Strategic Roundup | July 16–August 20, 2026
August 19, 2026